TRAIL as biomarker and potential therapeutic tool for cardiovascular diseases. Curr Drug Targets 2012;13(9):1215-21.
. Association of tumor necrosis factor-related apoptosis-inducing ligand with total and cardiovascular mortality in older adults. Atherosclerosis 2011;215(2):452-8.
. Circulating TRAIL shows a significant post-partum decline associated to stressful conditions. PLoS One 2011;6(12):e27011.
. Dasatinib plus Nutlin-3 shows synergistic antileukemic activity in both p53 wild-type and p53 mutated B chronic lymphocytic leukemias by inhibiting the Akt pathway. Clin Cancer Res 2011;17(4):762-70.
. miR-34a induces the downregulation of both E2F1 and B-Myb oncogenes in leukemic cells. Clin Cancer Res 2011;17(9):2712-24.
. Molecular targets for selective killing of TRAIL-resistant leukemic cells. Expert Opin Ther Targets 2011;15(8):931-42.
. Osteoprotegerin induces morphological and functional alterations in mouse pancreatic islets. Mol Cell Endocrinol 2011;331(1):136-42.
. Osteoprotegerin promotes vascular fibrosis via a TGF-β1 autocrine loop. Atherosclerosis 2011;218(1):61-8.
. Recent advances in the therapeutic perspectives of Nutlin-3. Curr Pharm Des 2011;17(6):569-77.
. Trail down-regulates the release of osteoprotegerin (OPG) by primary stromal cells. J Cell Physiol 2011;226(9):2279-86.
.